Perform Another (Advanced) Search

1.  Study Posting (5359) Trial #155049, Diabetic Foot Ulcers, West Reading, PA
...know have a Diabetic Foot Infection or Surgical Site Infection and in the hospital on antibiotics. If so, please contact Crystal Nagle at 610-988-4308 and see if this study ...
...for you. This is an observational study for patients already in the hospital and on antibiotic therapy. Patient Inclusion Criteria: • Diagnosis of Surgical Site Infection or Diabetic Foot Infection that requires ...
View Page

2.  Study Posting (2243) Trial #48883, Sinus Infections, Colorado Springs, CO
...48883, Sinus Infections, Colorado Springs, CO Trial Information Acute Sinusitis Study. Do you need an antibiotic for a sinus infection causing facial pain and colored nasal drainage? The study requires 5 ...
...done at no expense. A sinus culture will be obtained at the first visit. Study antibiotic will be provided along with compensation for time and travel. Eligibility Criteria: • 18 years or ...
View Page

3. Clinical Trial Results by Drug Names
...b.i.d. (1%) and 150 mg b.i.d. (3%) active treatment groups required antibiotics for the treatment of secondary illnesses than patients in the placebo group (5%) (see table ...
...002, respectively). Active treatment did not preclude a natural immune response to the viral infection. Antibiotic intervention for specified secondary illnesses (intent-to-treat infected population) 1 Placebo (n=161), n ...
View Page

4. Clinical Trial Results by Drug Names
...drug. Analysis of these data showed that more patients in the placebo group (11%) required antibiotic treatment for secondary illnesses than those in the 75 mg b.i.d. (6%) and ...
...pre-influenza) health status and ability to perform daily activity. Specified secondary illnesses with associated antibiotics (intent-to-treat infected population) 1 Placebo (n=129), n (%)   Oseltamivir 75 mg b.i ...
View Page

5.  Newly Approved Drug Therapies (750) Invanz, Merck,
...Approved November 2001 Treatment Area: Bacterial infections General Information Invanz is a once-daily injectable antibiotic approved for use in adults for the treatment of moderate to severe infections caused by ...
...Invanz exhibited an excellent safety profile and showed success rates equivalent to those of comparator antibiotics. Side Effects Adverse events associated with the use of Invanz may include (but are not ...
View Page

6.  Study Posting (3262) Trial #80037, Wounds, Houston, TX
...and abscesses Local doctors conducting a double blind research study of an I.V. intravenous antibiotics for 7 days. If you have: • Major abscesses requiring surgical incision/drainage • Deep extensive cellulities ...
View Page

7.  News: CenterWatch Monthly April 2008 Issue (Clinical Trials Today)
...Debarment Failures a Wake-Up Call for CROs, Drug Sponsors After Congressional hearings on the antibiotic Ketek, a Congressional committee issued a scathing report on the FDA’s debarment process. The ...
View Page

8.  Study Posting (799) Trial #156976, *Healthy Patient Studies, Boston, MA
...ALS Ceftriaxone Study Rationale Ceftriaxone is a semisynthetic, third generation cephalosporin. Cephalosporins are beta-lactam antibiotics approved by the FDA for the treatment of infections such as septicemia, pneumonia, meningitis, and ...
...Toan, L.I. Bruijn, Z.Z. Su, P. Gupta, and P.B. Fisher, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005. 433(7021): p. 73-7. Alison ...
View Page

9.  Study Posting (5359) Trial #155051, Urinary Tract Infections, West Reading, PA
...or Acute Pyelonephritis caused by gram negative bacteria. • Have received one dose or less of antibiotics. Patient Exclusion Criteria: • Greater than one dose of antibiotics administered prior to study enrollment. • Allergy to cephalosporin or carbapenem antibiotics. • Presence of concurrent infection ...
View Page

10.  Newly Approved Drug Therapies (374) Trovan, Pfizer,
...Status: Approved December 1997 Treatment Area: bacterial infections General Information Trovan (trovafloxacin), a broad-spectrum antibiotic, has been approved for the treatment of 14 bacterial infections. Mechanism of Action Trovan is a member of the quinolone class of antibiotics. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed by Piehead ...
View Page

11.  Study Posting (799) Trial #163139, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...ALS Ceftriaxone Study Rationale Ceftriaxone is a semisynthetic, third generation cephalosporin. Cephalosporins are beta-lactam antibiotics approved by the FDA for the treatment of infections such as septicemia, pneumonia, meningitis, and ...
...Toan, L.I. Bruijn, Z.Z. Su, P. Gupta, and P.B. Fisher, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005. 433(7021): p. 73-7. Alison ...
View Page

12.  Study Posting (799) Trial #163131, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...ALS Ceftriaxone Study Rationale Ceftriaxone is a semisynthetic, third generation cephalosporin. Cephalosporins are beta-lactam antibiotics approved by the FDA for the treatment of infections such as septicemia, pneumonia, meningitis, and ...
...Toan, L.I. Bruijn, Z.Z. Su, P. Gupta, and P.B. Fisher, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005. 433(7021): p. 73-7. Alison ...
View Page

13.  Study Posting (799) Trial #156966, Amyotrophic Lateral Sclerosis (ALS), Boston, MA
...ALS Ceftriaxone Study Rationale Ceftriaxone is a semisynthetic, third generation cephalosporin. Cephalosporins are beta-lactam antibiotics approved by the FDA for the treatment of infections such as septicemia, pneumonia, meningitis, and ...
...Toan, L.I. Bruijn, Z.Z. Su, P. Gupta, and P.B. Fisher, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005. 433(7021): p. 73-7. Alison ...
View Page

14.  Study Posting (1570) Trial #156494, Cystic Fibrosis, Morristown, NJ
...implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial ...
View Page

15.  CenterWatch: New Medical Therapies in Disease Category (119), Pharyngitis
...Advancis and Par have issued negative results of a phase III trial of their investigational antibiotic Amoxicillin PULSYS , for the treatment of Group A streptococcal pharyngitis/tonsillitis. Trial data failed to ...
View Page

16.  Newly Approved Drug Therapies (597) Tequin, Bristol-Myers Squibb,
...Status: December, 1999 Treatment Area: Community-acquired respiratory tract infections General Information The first quinolone antibiotic to come in bioequivalent 400 mg injectable and tablet formulations, this is a solution of ...
...growth of resistance of gram-positive bacteria. Therefore, it can treat some infections that other antibiotics like penicillin cannot. There were estimated to be 125 million cases of such infections last ...
View Page

17.  Newly Approved Drug Therapies (132) Merrem I.V. (meropenem), AstraZeneca,
...and for the treatment of bacterial meningitis in pediatric subjects. Merrem is the first carbapenem antibiotic available in the United States that can be used in children and does not need ...
...in combination with an enzyme inhibitor to prevent its renal breakdown. Merrem is a potent antibiotic with activity against many different bacteria, including some that are resistant to other antibiotics. Merrem ...
View Page

18.  Newly Approved Drug Therapies (720) Spectracef, TAP Pharmaceuticals,
...Approval Status: Approved August 2001 Treatment Area: Bacterial infections General Information Spectracef, a new cephalosporin antibiotic, has been approved in 400 mg tablet formulation for the treatment of acute exacerbations of ...
...are approved for use in adults and adolescents ages 12 and over. Similar to other antibiotics, it should be taken twice a day for a period of ten days. Clinical Results ...
View Page

19.  News: Ketek Hearing Winners and Losers (Clinical Trials Today)
...House Energy and Commerce’s Subcommittee on Oversight and Investigations probing study fraud and the antibiotic Ketek, one thing is clear: PPD, which monitored the study in question sponsored by Aventis ...
View Page

20.  Newly Approved Drug Therapies (439) Monurol, Forest Laboratories,
...Area: uncomplicated urinary tract infection General Information Monurol is the first one-time, one-dose antibiotic for uncomplicated urinary tract infection, as well as the first product of a new class of antibiotics. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed by Piehead ...
View Page